Fig. 4
From: GAD1 contributes to the progression and drug resistance in castration resistant prostate cancer
Exploring GAD1 gene mutations, methylation and clinicopathological features in prostate cancer. A GAD1 mutation rate. B–E Correlation between GAD1 gene mutations and clinicopathology, including T stage, Tumor level, initial diagnosis and Fraction genome altered. F Progression-free survival of GAD1 mutations. G Gene pathways influenced by GAD1 mutations. H–K Relevance of GAD1 promoter methylation to clinicopathology, including expressions, years, N stage and TP53 mutations. L Correlation of GAD1 with methylated genes. G1 represents GAD1-low expression and G2 represents GAD1-high expression